Search

Displaying results 4071 - 4080 of 9670 in total
  1. Drug

    Ophiocordyceps sinensis

    go.drugbank.com/drugs/DB19288
    Investigational

    Mixtures: Aps
  2. Drug

    Palopegteriparatide

    go.drugbank.com/drugs/DB18676
    ApprovedInvestigational

    [L51134] Palopegteriparatide was first approved by the EMA on November 17, 2023, for the treatment of hyperparathyroidism.[L51134] On August 8, 2024, palopegteriparatide was also approved by the FDA.

    Synonyms: Human parathyroid hormone (PTH) synthetic peptide fragment (1-34), conjugated at the N-terminal amino group via a cleavable linker to O-methylpolyethylene glycol (2 x 20 kDa mPEG); 2-methylalanyl-(1-34
  3. Drug

    Tiazofurine

    go.drugbank.com/drugs/DB13243
    Experimental

    Tiazofurine has potential clinical use in cancer treatment as it is a potential inhibitor of Inosine- 5’-monophosphate (IMP) dehydrogenase [A174991].

  4. Drug

    Pipecuronium

    go.drugbank.com/drugs/DB01338
    ApprovedInvestigationalWithdrawn

    Pipecuronium is a piperazinyl androstane derivative which is a non-depolarizing neuromuscular blocking agent.

  5. Drug

    AGRO100

    go.drugbank.com/drugs/DB04998
    Investigational

    well as malignant melanoma and leukemia. … AGRO100 is an oligonucleotide that functions as an aptamer and binds to nucleolin, a protein found intranuclear in all cells, but uniquely expressed on the surface of tumor cells.

  6. Drug

    Romiplostim

    go.drugbank.com/drugs/DB05332
    ApprovedInvestigational

    The peptibody molecule has two identical single-chain subunits, each one is made up of 269 amino acid residues.

  7. Drug

    Nadide

    go.drugbank.com/drugs/DB14128
    Investigational

    It is found widely in nature and is involved in numerous enzymatic reactions in which it serves as an electron carrier by being alternately oxidized (NAD+) and reduced (NADH). (Dorland, 27th ed)

  8. Drug

    NP2

    go.drugbank.com/drugs/DB06308
    Investigational

    It was under investigation in clinical trial NCT01291901 (NP2 Enkephalin For Treatment of Intractable Cancer Pain).

  9. Drug

    Zunsemetinib

    go.drugbank.com/drugs/DB16502
    Investigational

    Additionally, ATI-450 was studied in a terminated trial (NCT05511519) to treat patients with psoriatic arthritis. … ATI-450 was under investigation in clinical trials (NCT05279417 and NCT05216224) for treating patients with rheumatoid arthritis and hidradenitis suppurativa, respectively.

  10. Drug

    NNZ-2591

    go.drugbank.com/drugs/DB15601
    Investigational

    It was granted Orphan Drug Designation by the FDA in October 2019[L11103] and was granted a patent by the European Patent Office in December 2019. … [L11106] It is currently under development by Neuren Pharmaceuticals for the symptomatic treatment of Angelman, Phelan-McDermid, and Pitt Hopkins Syndromes.